Literature DB >> 25381466

Rare germline copy number deletions of likely functional importance are implicated in endometrial cancer predisposition.

Gemma L Moir-Meyer1, John F Pearson, Felicity Lose, Rodney J Scott, Mark McEvoy, John Attia, Elizabeth G Holliday, Paul D Pharoah, Alison M Dunning, Deborah J Thompson, Douglas F Easton, Amanda B Spurdle, Logan C Walker.   

Abstract

Endometrial cancer is the most common invasive gynaecological cancer in women, and relatively little is known about inherited risk factors for this disease. This is the first genome-wide study to explore the role of common and rare germline copy number variants (CNVs) in predisposition to endometrial cancer. CNVs were called from germline DNA of 1,209 endometrioid endometrial cancer cases and 528 cancer-unaffected female controls. Overall CNV load of deletions or DNA gains did not differ significantly between cases and controls (P > 0.05), but cases presented with an excess of rare germline deletions overlapping likely functional genomic regions including genes (P = 8 × 10(-10)), CpG islands (P = 1 × 10(-7)) and sno/miRNAs regions (P = 3 × 10(-9)). On average, at least one additional gene and two additional CpG islands were disrupted by rare deletions in cases compared to controls. The most pronounced difference was that over 30 sno/miRNAs were disrupted by rare deletions in cases for every single disruption event in controls. A total of 13 DNA repair genes were disrupted by rare deletions in 19/1,209 cases (1.6%) compared to one gene in 1/528 controls (0.2%; P = 0.007), and this increased DNA repair gene loss in cases persisted after excluding five individuals carrying CNVs disrupting mismatch repair genes MLH1, MSH2 and MSH6 (P = 0.03). There were 34 miRNA regions deleted in at least one case but not in controls, the most frequent of which encompassed hsa-mir-661 and hsa-mir-203. Our study implicates rare germline deletions of functional and regulatory regions as possible mechanisms conferring endometrial cancer risk, and has identified specific regulatory elements as candidates for further investigation.

Entities:  

Mesh:

Year:  2014        PMID: 25381466     DOI: 10.1007/s00439-014-1507-4

Source DB:  PubMed          Journal:  Hum Genet        ISSN: 0340-6717            Impact factor:   4.132


  49 in total

Review 1.  Endometrioid carcinoma of the uterine corpus: a review of its pathology with emphasis on recent advances and problematic aspects.

Authors:  Philip B Clement; Robert H Young
Journal:  Adv Anat Pathol       Date:  2002-05       Impact factor: 3.875

2.  A novel method to compensate for different amplification efficiencies between patient DNA samples in quantitative real-time PCR.

Authors:  J Meijerink; C Mandigers; L van de Locht; E Tönnissen; F Goodsaid; J Raemaekers
Journal:  J Mol Diagn       Date:  2001-05       Impact factor: 5.568

Review 3.  Germline copy number variations and cancer predisposition.

Authors:  Ana Cristina Victorino Krepischi; Peter Lees Pearson; Carla Rosenberg
Journal:  Future Oncol       Date:  2012-04       Impact factor: 3.404

4.  Relationship of the aberrant DNA hypermethylation of cancer-related genes with carcinogenesis of endometrial cancer.

Authors:  Kouji Banno; Megumi Yanokura; Nobuyuki Susumu; Makiko Kawaguchi; Nobumaru Hirao; Akira Hirasawa; Katsumi Tsukazaki; Daisuke Aoki
Journal:  Oncol Rep       Date:  2006-12       Impact factor: 3.906

5.  Hypermethylation of miR-203 in endometrial carcinomas.

Authors:  Yi-Wen Huang; Chieh-Ti Kuo; Jo-Hsin Chen; Paul J Goodfellow; Tim H-M Huang; Janet S Rader; Denise S Uyar
Journal:  Gynecol Oncol       Date:  2014-02-14       Impact factor: 5.482

6.  Genome-wide association study identifies a common variant associated with risk of endometrial cancer.

Authors:  Amanda B Spurdle; Deborah J Thompson; Shahana Ahmed; Kaltin Ferguson; Catherine S Healey; Tracy O'Mara; Logan C Walker; Stephen B Montgomery; Emmanouil T Dermitzakis; Paul Fahey; Grant W Montgomery; Penelope M Webb; Peter A Fasching; Matthias W Beckmann; Arif B Ekici; Alexander Hein; Diether Lambrechts; Lieve Coenegrachts; Ignace Vergote; Frederic Amant; Helga B Salvesen; Jone Trovik; Tormund S Njolstad; Harald Helland; Rodney J Scott; Katie Ashton; Tony Proietto; Geoffrey Otton; Ian Tomlinson; Maggie Gorman; Kimberley Howarth; Shirley Hodgson; Montserrat Garcia-Closas; Nicolas Wentzensen; Hannah Yang; Stephen Chanock; Per Hall; Kamila Czene; Jianjun Liu; Jingmei Li; Xiao-Ou Shu; Wei Zheng; Jirong Long; Yong-Bing Xiang; Mitul Shah; Jonathan Morrison; Kyriaki Michailidou; Paul D Pharoah; Alison M Dunning; Douglas F Easton
Journal:  Nat Genet       Date:  2011-04-17       Impact factor: 38.330

7.  MicroRNA-203 suppresses cell proliferation and migration by targeting BIRC5 and LASP1 in human triple-negative breast cancer cells.

Authors:  Chen Wang; Xiangqian Zheng; Chunyan Shen; Yurong Shi
Journal:  J Exp Clin Cancer Res       Date:  2012-06-19

8.  Galaxy: a comprehensive approach for supporting accessible, reproducible, and transparent computational research in the life sciences.

Authors:  Jeremy Goecks; Anton Nekrutenko; James Taylor
Journal:  Genome Biol       Date:  2010-08-25       Impact factor: 13.583

9.  Rare copy number variants observed in hereditary breast cancer cases disrupt genes in estrogen signaling and TP53 tumor suppression network.

Authors:  Katri Pylkäs; Mikko Vuorela; Meeri Otsukka; Anne Kallioniemi; Arja Jukkola-Vuorinen; Robert Winqvist
Journal:  PLoS Genet       Date:  2012-06-21       Impact factor: 5.917

10.  QuantiSNP: an Objective Bayes Hidden-Markov Model to detect and accurately map copy number variation using SNP genotyping data.

Authors:  Stefano Colella; Christopher Yau; Jennifer M Taylor; Ghazala Mirza; Helen Butler; Penny Clouston; Anne S Bassett; Anneke Seller; Christopher C Holmes; Jiannis Ragoussis
Journal:  Nucleic Acids Res       Date:  2007-03-06       Impact factor: 16.971

View more
  6 in total

1.  Candidate predisposing germline copy number variants in early onset colorectal cancer patients.

Authors:  A J Brea-Fernandez; C Fernandez-Rozadilla; M Alvarez-Barona; D Azuara; M M Ginesta; J Clofent; L de Castro; D Gonzalez; M Andreu; X Bessa; X Llor; R Xicola; R Jover; A Castells; S Castellvi-Bel; G Capella; A Carracedo; C Ruiz-Ponte
Journal:  Clin Transl Oncol       Date:  2016-11-25       Impact factor: 3.405

Review 2.  The Role of Constitutional Copy Number Variants in Breast Cancer.

Authors:  Logan C Walker; George A R Wiggins; John F Pearson
Journal:  Microarrays (Basel)       Date:  2015-09-08

Review 3.  Metformin as a Therapeutic Target in Endometrial Cancers.

Authors:  Teresa Y Lee; Ubaldo E Martinez-Outschoorn; Russell J Schilder; Christine H Kim; Scott D Richard; Norman G Rosenblum; Jennifer M Johnson
Journal:  Front Oncol       Date:  2018-08-28       Impact factor: 6.244

4.  Overexpression of <em>MYBL2</em> predicts poor prognosis and promotes oncogenesis in endometrial carcinoma.

Authors:  Lulu Le; Ji Luo; Haifang Wu; Ling Chen; Xiaoli Tang; Fen Fu
Journal:  Eur J Histochem       Date:  2021-03-30       Impact factor: 3.188

5.  Germline copy number variations are associated with breast cancer risk and prognosis.

Authors:  Mahalakshmi Kumaran; Carol E Cass; Kathryn Graham; John R Mackey; Roland Hubaux; Wan Lam; Yutaka Yasui; Sambasivarao Damaraju
Journal:  Sci Rep       Date:  2017-11-07       Impact factor: 4.379

6.  Integrative analysis of genomic and epigenetic regulation of endometrial cancer.

Authors:  Qihang Zhong; Junpeng Fan; Honglei Chu; Mujia Pang; Junsheng Li; Yong Fan; Ping Liu; Congying Wu; Jie Qiao; Rong Li; Jing Hang
Journal:  Aging (Albany NY)       Date:  2020-05-15       Impact factor: 5.682

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.